GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Alar Pharmaceuticals 6785.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

76.50

+3.66%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Alar Pharmaceuticals

Its shares trade on Taipei Exchange under the ticker 6785.TWO. It has been listed since 5 October 2020. In the fiscal year to 31 December 2025, it reported revenue of TWD 2.8m and a net loss of TWD 79.7m. At that date it held total assets of TWD 2.49bn and shareholders' equity of TWD 2.40bn.

Alar Pharmaceuticals, Inc. engages in the development of long-acting release drug products for CNS disorders and chronic diseases. The company is headquartered in Taichung, Taichung. The company went IPO on 2020-10-05. The main products include ALA-1000, which is buprenorphine (buprenorphine) subcutaneous long-acting sustained-release injection, indicated for opioid addiction (OUD); ALA-1100, which is buprenorphine (buprenorphine) long-acting subcutaneous injection Release injection, indicated for chronic pain (Chronic Pain); and ALA-3000 , which is long-acting sustained release injection, indicated for refractory depression (TRD). The firm distributes its products and services within United States, Europe and Asia markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
5 Oct 2020

Leadership

Pay as last reported

  • Mr. Tung-He LinChairman of the Board
  • Yongshun WenGeneral Manager
  • Yuning KangHead of Finance & Accounting, Corporate Governance Officer
  • Chengyou FangDirector
  • Jingwen WangDirector
  • Shuisheng LiIndependent Director
  • Ms. Shuqin LiangIndependent Director
  • Meili SuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Develops long-acting release drug products for CNS disorders and chronic diseases.
  • Headquartered in Taichung, Taiwan, with IPO in 2020.
  • Offers three main products targeting opioid addiction, chronic pain, and refractory depression.

Weaknesses

  • Operates in a highly regulated pharmaceutical sector.
  • Relies on specific drug products for market presence.
  • Distributes products in multiple regions with potential regulatory challenges.

Opportunities

  • Expands into United States, Europe, and Asia markets for product distribution.
  • Growth potential in CNS disorders and chronic disease treatment segments.
  • Long-acting drug products may address unmet medical needs.

Threats

  • Regulatory hurdles in multiple international markets.
  • Competition in pharmaceutical development for CNS disorders.
  • Dependence on specific drug product success for company growth.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.